Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus standard induction therapy in newly diagnosed AML ≤60 years
2008-004968-40Phase 2Completed
- Sponsor
- Technische Universität Dresden
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Sorafenib + standard primary therapy with Placebo + standard primary therapy (2 arms). Primary endpoints: Event-free survival (overall AML population) and Event-free survival (FLT3-ITD–mutated subgroup). Started Nov 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2008-004968-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004968-40.